lundi 16 novembre 2026
RechercherExplore
Via News Knowledge File

Eli Lilly and Company

organization80% conf.·synced Nov 16, 2026

Pharmaceutical company with gene therapy licensing deal with REGENXBIO

60
sourced metrics
1308
relationships
20
stated objectives
1
Via News reports
Working data, not the finished story. This is what our AI has read and extracted from source documents so far. Before anything here becomes news, it is checked against the original source, fact-checked and put in context. Figures can be incomplete or wrongly labelled at this stage; our articles are the end product. How we source

Key metrics · each point sourced

Price 52 Week High
$1,443.5
Nov 13, 2026reference only
Stock Return Ytd
33.61%
Nov 13, 2026reference only
Price 52 Week Low
$851.21
Nov 13, 2026reference only
Market Cap
$1.36T
Nov 13, 2026reference only
Stock Price
$1,443.5
Nov 13, 2026reference only
Shares Outstanding
940.7Mshares
Oct 26, 2026reference only
Eps
7.22USD per share
Sep 30, 2026reference only
Revenue
$24.4B
Sep 30, 2026reference only
Net Income
$6.45B
Sep 30, 2026reference only
Stockholders Equity
$40.27B
Sep 30, 2026reference only
Cash
$4.88B
Sep 30, 2026reference only
Cost Of Revenue
$3.93B
Sep 30, 2026reference only
Total Assets
$148.07B
Sep 30, 2026reference only
Operating Cash Flow
$5.33B
Mar 31, 2026reference only

Stated objectives

Obtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC

source
stated

Advance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer

source
stated

Demonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer

source
stated

Show sustained IDFS/DRFS improvements and OS prolongation in monarchE trial across nodal status subgroups

source
stated

Translate biologic conviction into meaningful progress by addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K

source
stated

Demonstrate non-inferiority of pirtobrutinib versus ibrutinib on overall response rate in CLL/SLL patients

source
target: non-inferiority on ORR stated

Complete formal PFS analysis testing for superiority of pirtobrutinib

source
target: superiority on PFS stated

Verify and describe clinical benefit of Jaypirca in confirmatory trials to maintain accelerated approval status

source
target: clinical benefit verification stated

Demonstrate pirtobrutinib's potential role across treatment settings and B-cell malignancies through development program

source
stated

Receive regulatory approvals for pirtobrutinib in earlier disease settings to expand treatment options for patients

source
target: regulatory approval by 2026-01-01 00:00:00stated

Relationship graph · 1308 connections

Developed by
526
Competes with
205
Employs
86
Covered by
58
Acquired by
54
Regulates
46
Headquartered in
45
Located in
27

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →